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Abstract Chronic kidney disease (CKD) occurs in all age
groups, including children. Regardless of the underlying
cause, CKD is characterized by progressive scarring that
ultimately affects all structures of the kidney. The relentless
progression of CKD is postulated to result from a self-
perpetuating vicious cycle of fibrosis activated after initial
injury. We will review possible mechanisms of progressive
renal damage, including systemic and glomerular hyperten-
sion, various cytokines and growth factors, with special
emphasis on the renin–angiotensin–aldosterone system
(RAAS), podocyte loss, dyslipidemia and proteinuria. We
will also discuss possible specific mechanisms of tubuloin-
terstitial fibrosis that are not dependent on glomeruloscle-
rosis, and possible underlying predispositions for CKD,
such as genetic factors and low nephron number.
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Introduction
Chronic kidney disease (CKD) occurs in all age groups,
with an incidence in children between 1.5 per million and
3.0 per million. Renal developmental abnormalities (con-
genital abnormalities of the kidney and urinary tract,
CAKUT) are the most common causes of CKD in children.
Other diseases commonly underlying CKD in children
include focal segmental glomerulosclerosis (FSGS), hemo-
lytic uremic syndrome (HUS), immune complex diseases,
and hereditary nephropathies, such as Alport’s disease [1].
The incidence of diabetes, especially type 2, is increasing in
children. Although CKD secondary to diabetes usually does
not develop until adulthood, early structural lesions of
diabetic nephropathy start in childhood [2].
CKD shares a common appearance of glomeruloscle-
rosis, vascular sclerosis and tubulointerstitial fibrosis,
suggesting a common final pathway of progressive injury
[3]. Adaptive changes in nephrons after initial injury are
postulated ultimately to be maladaptive, eventually causing
scarring and further nephron loss, thus perpetuating a
vicious cycle that results in the end-stage kidney. We will
review possible mechanisms of progressive renal damage,
which include, but are not limited to, hemodynamic factors,
the renin–angiotensin–aldosterone system (RAAS), various
cytokines and growth factors, podocyte loss, dyslipidemia,
proteinuria, specific mechanisms of tubulointerstitial fibro-
sis, and possible underlying predispositions for CKD, such
as genetic factors and low nephron number.
Systemic and glomerular hypertension
Systemic hypertension often accompanies renal disease and
may both result from, and contribute to, CKD. Progression
of CKD is accelerated by hypertension, and control of
blood pressure is key in the treatment of CKD. In addition,
the glomerulus has a unique structure, with both an afferent
and an efferent arteriole, which permits modulation of
glomerular perfusion and pressure without corresponding
systemic blood pressure change.
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to investigate CKD [4]. In this model, one kidney and
infarction/removal of two-thirds of the remaining kidney
(i.e. five-sixths nephrectomy) results in progressive hyper-
perfusion, hyperfiltration, hypertrophy and FSGS [4–6].
Additional models with initial podocyte injury, namely the
puromycin aminonucleoside and adriamycin models of
renal disease, show initial proteinuria and podocyte damage
similar to human minimal-change disease, followed by
progressive FSGS [7].
Direct micropuncture studies have demonstrated that
single nephron function was increased after renal ablation,
andledtothehypothesisthathyperfiltrationcausedsclerosis,
setting in motion a vicious cycle of hyperfiltration and
glomerulosclerosis [3, 8]. Maneuvers that decreased hyper-
filtration, such as low-protein diet, angiotensin I converting
enzyme inhibitors (ACEIs), lipid-lowering agents, or
heparin, were, indeed, effective in ameliorating glomerular
sclerosis. However, in some studies, glomerular sclerosis
was decreased without altering glomerular hyperfiltration
[9], and glomerular sclerosis occurred in some settings even
in the absence of intervening hyperperfusion [10].
Thus, focus was shifted to glomerular hypertension as a
key mediator of progressive sclerosis. Maneuvers that
increase glomerular capillary pressure, such as therapy with
erythropoietin, glucocorticoids, or high-protein diet, accel-
erated glomerulosclerosis, while decreasing glomerular
pressure ameliorated sclerosis. These beneficial effects were
particularly apparent in the comparison of agents such as
ACEIs that preferentially decrease glomerular pressure even
more than systemic BP to non-specific antihypertensive
agents [11].
Renin–angiotensin–aldosterone system
The RAAS hasbeenthe focusof investigationof progression
in CKD because of the efficacy of inhibition of its
components in CKD. ACEIs decrease glomerular capillary
pressure by preferential dilation of the efferent arteriole [1],
likely mediated by both inhibition of angiotensin II (AngII)
and especially by the effect of ACEIs in augmenting
bradykinin, which is degraded by angiotensin I converting
enzyme (ACE) [12]. Indeed, angiotensin type 1 receptor
blockers (ARBs), which do not have this activity to increase
bradykinin, do not preferentially dilate the efferent arteriole
or decrease glomerular pressures to the extent of that seen
with ACEIs in most experimental studies. However, both
ACEIs and ARBs have shown superior efficacy in slowing
progressive CKD in experimental models and in human
CKD [13–16].
ARBs leave the angiotensin type 2 (AT2) receptor active,
and may in theory even lead to augmented AT2 effects by
allowing unbound AngII to bind to this receptor. The AT2
receptor counteracts some of the classic AT1 receptor
actions and thus is mildly vasodilating and mediates growth
inhibition and apoptosis [17–20]. Apoptosis often is
associated with decreased injury, as injured cells are
quickly removed without activation of profibrotic cytokines
and chemokines. Absence of AT2 receptor actions, either
by pharmacological inhibition or by genetic absence,
indeed resulted in diminished apoptosis after injury,
associated with increased fibrosis [21, 22].
Combined ACEI and AT1 receptor antagonist treatment
could have a theoretic advantage, allowing further blockade
of AngII actions while maintaining preferential local avail-
ability of the AT2 receptor [23]. In an experimental model,
combined ACEI and ARB therapy did not result in added
benefit on glomerulosclerosis when compared with single-
drug therapy with similar blood pressure control [24, 25].
However, addition of AT2 receptor inhibition to ARB
treatment prevented the beneficial effects of ARBs [26]. A
beneficial effect of the AT2 receptor in renal injury was also
demonstrated in transgenic mice overexpressing the AT2
receptor. These mice developed less severe injury than did
the wild type after subtotal nephrectomy [27]. Results from
small clinical studies of human CKD suggest that the
combination of ARBs and ACEIs has greater effect in the
decrease of proteinuria, not attributable to effects on
systemic blood pressure [28, 29]. In a large study of
hypertensive patients with diabetic nephropathy and micro-
albuminuria, combined therapy resulted in greater reduction
of blood pressure and albuminuria than did therapy with
either drug alone [30]. In a Japanese study, in addition to
decreased proteinuria, the slope of decline of glomerular
filtration rate (GFR) improved with combination ACEI and
ARB versus monotherapy [31]. However, complete dose-
range comparisons of combined therapy with monotherapy
were not made in these clinical trials. A recent review of
clinical trials with combination therapy with ACEI and
ARB in CKD patients support that such combination
therapy had increased effects to decrease proteinuria
without significantly increasing adverse side effects [16].
Antifibrotic effects of combination therapy versus
monotherapy could include augmented bradykinin and
AT2 activity and also decreased urinary transforming
growth factor (TGF)-β [32]. In addition, there may be
greater suppression of the renin–angiotensin system (RAS)
with combined therapy, decreasing both ligand generation
by inhibition of ACE and binding of any remaining AngII
to the AT1 receptor. However, even suprapharmacological
doses of ACE inhibition did not achieve complete suppres-
sion of the local RAS in experimental models [33].
Similarly, patients receiving ACEIs long term still have
measurable ACE in their plasma. These data support the
notion that non-ACE-dependent AngII generation by
chymotrypsin-sensitive generating enzyme occurs in
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development of renin antagonists that could obviate these
obstacles to optimal inhibition of the RAAS. Renin itself
may have direct effects, independent of activation of the
RAAS, with renin receptor activity detected on mesangial
cells [34].
Many profibrotic actions of the RAAS are mediated
directly by AngII. AngII promotes migration of endothelial
and vascular smooth muscle cells, and hypertrophy and
hyperplasia of smooth muscle cells and mesangial cells [35,
36]. All components of the RAS are present in macrophages,
which may thus serve as yet another source of AngII and
also respond to ACEI and ARB. AngII also induces other
growth factors, including basic fibroblast growth factor
(basic FGF), platelet-derived growth factor (PDGF) and
TGF-β, and plasminogen activator inhibitor-1 (PAI-1), all of
which may impact on fibrosis (see below), [37–39].
Importantly, new data indicate that aldosterone has both
genomic and non-genomic actions to promote fibrosis,
independent of its actions to increase blood pressure by
mediating salt retention [40, 41]. Aldosterone enhances
angiotensin induction of PAI-1 (see below), and also has
direct actions on fibrosis [40]. Conversely, aldosterone
receptor antagonism with spironolactone decreased injury
[40]. PAI-1 deficiency prevented aldosterone-induced glo-
merular injury, but interestingly did not alter cardiac or
aortic injury in this mouse model, suggesting site-specific
and perhaps species-specific mechanisms of aldosterone-
PAI-1 mediated fibrosis [42]. In clinical trials, aldosterone
antagonism has further decreased proteinuria when added to
ACEI and ARB therapy [43, 44]. However, the potential
risk of hyperkalemia may limit the ability to add aldoste-
rone antagonism to angiotensin inhibition. Whether these
approaches also apply to children with CKD has not been
investigated.
Clearly, the RAAS has many non-hemodynamic actions
and thus, doses beyond usual antihypertensive doses are
potentially of additional benefit. Regression has even been
achieved in experimental models with high-dose ACEI/
ARB. A shift in the balance of synthesis/degradation of
extracellular matrix (ECM) must occur to accomplish
regression of sclerosis; endothelial cells must regenerate,
mesangial cells must regrow, and finally, podocytes must be
restored. New glomeruli cannot be generated after term
birth in humans. However, remaining segments of non-
sclerotic loops can give rise to more open capillary area by
lengthening or branching of the remaining capillaries [45–
48]. Recent experimental data show that regression can,
indeed, be induced by high-dose ACEI or ARB or
spironolactone, linked to decreased PAI-1, restored plasmin
activity and capillary remodeling [25, 49–51]. Of note,
regression was not associated with increased expression or
activity of matrix metalloproteases-2 or -9 or decreased
mRNA for TGF-β or local decreases in TGF-β expression
as assessed by in situ hybridization. However, lack of
changes in mRNA does not rule out that local changes in
TGF-β actions could occur, and clearly, in many systems,
TGF-β has been shown to impact on ECM accumulation.
Regression is also possible in human CKD, demonstrated in
principle by regression of early diabetic sclerosis and
tubulointerstitial fibrosis in patients over a 10-year period
when the underlying diabetes was cured by pancreas
transplantation [52]. Regression of existing lesions also
occurred in IgA nephropathy in response to high-dose
corticosteroids and tonsillectomy [53].
Specific cytokines/growth factors and progression of CKD
Numerous cytokines/growth factors appear to modulate
progression of glomerular and tubulointerstitial scarring.
These factors and their roles may differ at the various stages
of injury. Altered gene expressions and/or pharmacologic
manipulations in pathophysiological settings have implicated
e.g. PDGF, TGF-β, AngII, basic FGF, endothelin, various
chemokines, peroxisome proliferator-activated receptor-γ
(PPAR-γ) and PAI-1, among others, in progressive renal
scarring [10, 54–56]. Current state-of-the-art approaches
with proteomic and array analysis of renal tissue in human
CKD and in animal models can identify novel targets and
markers, and even mediators of progression [57, 58]. Of
these many potential molecules of interest, we will discuss
only a few that have been investigated in depth.
Increased PAI-1 is associated with increased cardiovas-
cular disease and fibrotic kidney disease [59]. Conversely,
PAI-1 could be decreased by inhibition of AngII and/or
aldosterone, and linked to prevention of sclerosis or even
regression of existing kidney fibrosis [25, 38, 51, 60].
AngII and aldosterone can also induce PAI-1 expression
and subsequent fibrosis independent of TGF-β activation
[61]. Some of the effects of PAI-1 in promoting fibrosis are
independent of its effects on proteolysis. PAI-1 also
modulates cell migration, perhaps by its effects on
vitronectin interaction [59]. Thus, PAI-1 may in some
inflammatory or interstitial disease settings increase fibrosis
primarily by enhancing cell migration and epithelial-
mesenchymal transition (EMT). In contrast, in the glomer-
ulus, the effects of PAI-1 in the increase of sclerosis may
predominantly be due to its ability to modulate ECM
turnover [59]. These data support that mechanisms of
fibrosis in the interstitium and glomerulus are not identical,
and involve complex interactions of parenchymal and
infiltrating cells and cytokines, with variable net effects
on ECM accumulation.
TGF-β promotes ECM synthesis and is a key promoter
of fibrosis. The biological actions of TGF-β are complex
and depend not only on cell state, but also on the presence
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which can bind and modify its activity [37]. TGF-β also
induces both PAI-1 and AngII [62]. Animals transgenic for
TGF-β developed progressive renal disease [63]. Converse-
ly, inhibition of either TGF-β or PDGF-B decreased
mesangial matrix expansion in the anti-Thy1 model [64,
65]. Animals genetically deficient for TGF-β develop
lymphoproliferative disease, thought to reflect a loss of
TGF-β immune regulatory effect [66]. Interestingly, phar-
macologic inhibition of TGF-β was more effective at lower
dose, and with higher dose of anti-TGF-β associated with
more fibrosis and greater macrophage influx, perhaps also
reflecting effects on TGF-β immune modulation [67]. TGF-
β may promote a more fibroblastic phenotype of the
podocyte, with loss of differentiation markers and de novo
expression of alpha-smooth muscle actin [68]. Although
TGF-β promotes growth arrest and differentiation of
podocytes at low doses, at higher doses, TGF-β causes
podocyte apoptosis, mediated by Smad 7 signaling [69, 70].
Loss of podocytes (see below) is a key factor contributing
to progressive kidney fibrosis.
PPAR-γ modifies numerous cytokines and growth
factors, including PAI-1 and TGF-β. PPAR-γ is a tran-
scription factor and a member of the steroid superfamily
[71]. On activation, PPAR-γ binds the retinoic acid X
receptor, translocates to the nucleus and binds to peroxi-
some proliferator activator response elements (PPREs) in
selected target genes, modifying their expression. PPAR-γ
agonists, such as the thiazolidinediones, are most common-
ly used to treat type 2 diabetes, due to their beneficial
effects to increase insulin sensitivity and improve lipid
metabolism, and they have been shown to decrease diabetic
injury correspondingly in diabetic animal models [72].
Interestingly, PPAR-γ agonists also have antifibrotic effects
in non-diabetic or non-hyperlipidemic experimental models
of CKD. PPAR-γ agonist ameliorated the development of
sclerosis in these non-diabetic models, linked to decreased
PAI-1 and TGF-β and decreased infiltrating macrophages
and protection of podocytes against injury [56, 73]. Further
study is necessary to determine the specific role each of the
above factors plays at varying stages of renal fibrosis.
Podocyte loss
Podocytes are the primary target in many glomerular
diseases, including FSGS and the experimental models of
adriamycin and puromycin aminonucleoside-induced ne-
phropathies [74]. The podocytes are pivotal for mainte-
nance of normal permselectivity, and are a source of matrix
in both physiological and pathophysiological settings. The
podocyte does not normally proliferate. Loss of podocytes
after injury is postulated to be a key factor resulting in
progressive sclerosis [74]. This principle was proven in
experimental models in mice and rats, where podocyte-
specific injury was produced by genetic manipulation of the
podocytes to express toxin receptors only on this cell [75,
76]. Injection of toxin then resulted in podocyte loss, the
degree of which depended on toxin dose. Animals
subsequently developed progressive sclerosis. Of interest,
even though only podocytes were initially injured, subse-
quent injury rapidly also developed in endothelial and
mesangial cells, with resulting sclerosis. Even when
chimeric mice were genetically engineered so that only a
portion of their podocytes was susceptible to the toxin, all
podocytes developed injury after toxin exposure [77].
These data show that injury can also spread from the
initially injured podocyte to initially intact podocytes within
a glomerulus, setting up a vicious cycle of progressive
injury at the glomerular level [77].
The limited proliferation in the mature podocyte is
accompanied by high expression of a cyclin-dependent
kinase inhibitor, p27kip1, a rate-limiting step for the growth
response of the podocyte [78]. Either too much or too little
proliferation of the podocyte in response to genetic
manipulation of p27kip1 is postulated be detrimental [79].
Inadequate growth of the podocyte is postulated to give rise
to areas of dehiscence and insudation of plasma proteins,
which progress to adhesions and sclerosis [80]. Another
cyclin-dependent kinase inhibitor, p21, appears to be nec-
essary for development of injury after five-sixths nephrec-
tomy in mice, pointing to the crucial importance of cell
growth responses in determining response to injury [81].
Podocytes normally produce an endogenous heparin-like
substance, which inhibits mesangial cell growth; thus,
injury may decrease this growth inhibitory effect and allow
increased mesangial growth. Podocytes are also the main
renal source of angiopoietin-1 and vascular endothelial
growth factor (VEGF), an endothelial cell-specific mitogen
that plays a key role in both physiologic and pathologic
angiogenesis and vascular permeability [82]. Overexpres-
sion or partial loss of podocyte VEGF results in a
collapsing lesion or pre-eclampsia-like endotheliosis lesion,
respectively [82].
Podocyte genes and CKD
New studies of the molecular biology of the podocyte and
identification of genes mutated in rare familial forms of
FSGS and nephrotic syndrome, such as nephrin, WT-1,
transient receptor potential cation channel-6 (TRPC-6),
phospholipase C epsilon, α-actinin-4 and podocin, have
given important new insights into mechanisms of progres-
sive glomerulosclerosis. The gene mutated for congenital
nephrotic syndrome, nephrin (NPHS1) is localized to the
slit diaphragm of the podocyte and is tightly associated
with CD2-associated protein (CD2AP) [83]. Nephrin
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together with CD2AP, provides a crucial role in receptor
patterning and cytoskeletal polarity and also provides
signaling function of the slit diaphragm [84]. Mice with
CD2AP knockout develop congenital nephrotic syndrome,
similar to congenital nephrotic syndrome of Finnish type
[85]. Autosomal dominant FSGS with adult onset is caused
by mutation in α-actinin 4 (ACTN4) [86]. This is
hypothesized to cause altered actin–cytoskeleton interac-
tion, causing FSGS through a gain-of-function mechanism,
in contrast to the loss-of-function mechanism implicated for
disease caused by the nephrin mutation [85]. Patients with
α-actinin 4 mutation progress to end-stage by age 30 years,
with rare recurrence in a transplant. TRPC-6 encodes for a
cation channel, which is present in several sites including
podocytes. TRPC-6 is mutated in some kindreds with
familial FSGS with adult onset in an autosomal dominant
pattern [87]. Podocin, another podocyte-specific gene
(NPHS2), is mutated in autosomal recessive FSGS with
childhood onset with rapid progression to end-stage kidney
disease [88]. Podocin interacts with the CD2AP-nephrin
complex, indicating that podocin could serve in the
structural organization of the slit diaphragm. In some series
of steroid-resistant pediatric patients with non-familial
forms of FSGS, a surprisingly high proportion, up to
25%, had podocin mutations [89, 90]. However, not all
patients with nephrotic syndrome caused by mutation are
steroid resistant. Diffuse mesangial sclerosis in a large
kindred was recently linked to a truncating mutation of
phospholipase C epsilon (PLCE1), and two of those
patients responded to steroid therapy [91]. However, in
two patients with missense mutation of this same gene,
FSGS lesions developed, demonstrating that a spectrum of
structural abnormalities may arise from varying mutations
in the same gene. PLCE1 is expressed in the glomerulus,
where it is postulated to play a key role in development,
perhaps by interacting with other proteins that are crucial
for the development and function of the slit diaphragm.
WT-1 mutation, which may occur sporadically with only
FSGS or be associated with Denys–Drash syndrome, was
found in only 5% of steroid-resistant patients [92].
Interestingly, mutations of podocin or WT-1 were not found
in relapsing or steroid-dependent pediatric patients [93].
Acquired disruption or polymorphisms of some of these
complexly interacting molecules have been demonstrated in
experimental models and in human proteinuric diseases.
Thus, in puromycin aminonucleoside nephropathy, a model
of FSGS, nephrin localization and organization were altered
[94]. Similar decreases in nephrin were observed in
hypertensive diabetic rat models with significant proteinuria
[95]. TRPC-6, a calcium channel, was induced in various
non-genetic human proteinuric diseases [96]. Conversely,
treatments that ameliorated these experimental models
preserved e.g. glomerular nephrin expression, providing
further support for a key causal role for slit diaphragm and
key podocyte molecules in proteinuria [97]. Whether
polymorphisms, compound heterozygosity for mutations
or merely altered distribution and/or expression of any of
these proteins contribute to proteinuria or progressive
disease in various causes of CKD in humans has not been
determined.
Dyslipidemia
Patients with CKD frequently have dyslipidemia and
greatly increased cardiovascular disease risk, even beyond
that predicted by lipid abnormalities [98]. Abnormal lipids
are important in modulating glomerular sclerosis in rats;
however, analogous studies in humans are still evolving
[99–102]. Glomerular injury was increased in experimental
CKD when excess cholesterol was added to the diets.
Glomerular disease has been reported in the rare familial
disease, lecithin cholesterol acyltransferase deficiency, and
with excess apolipoprotein E. However, renal disease is not
typical in the more common forms of primary hyper-
lipidemias. Patients with minimal-change disease or mem-
branous glomerulonephritis, characterized by hyperlipidemia
as part of their nephrotic syndrome, usually do not develop
glomerular scarring. However, recently, post hoc and meta-
analyses of clinical trial data support that abnormal lipids are
associated with increased loss of GFR and that treatment with
statins may not only benefit cardiovascular disease risk, but
also be of benefit for progressive CKD. A post hoc analysis
suggests that statins may even slow progression in patients
with stage 3 CKD [102]. These beneficial effects of statins
appear to extend beyond their lipid-lowering effects [98, 101].
Proteinuria
Proteinuria is a marker of renal injury, reflecting loss of
normal permselecitvity. Further, proteinuria itself has been
proposed to contribute to progressive renal injury inflam-
mation [74, 103]. Increased proteinuria is associated with
worse prognosis [104]. Whether proteinuria is merely a
marker of injury or a contributor to progressive injury has
been debated.
Albumin can in vitro in tubular cells increase AngII and
in turn upregulate TGF-β receptor expression [105].
However, in most settings, pure albumin per se is not
directly injurious. Other filtered components of the urine in
proteinuric states, such as oxidized proteins, appear to be
more potent in inducing direct injury of tubular epithelial
cells and activating proinflammatory and fibrotic chemo-
kines and cytokines. Complement and various lipoproteins
are also present in the urine in proteinuric disease states and
can activate reactive oxygen species [101, 106]. Proteinuria
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contributing to a more profibrotic phenotype, and also
augment interstitial inflammation, in particular by macro-
phages. Proteinuria may activate many profibrotic pathways
through its ability to increase NF-kB, and also by other
pathways. These include for instance complement synthesis
from tubules [107].
Interventions that are particularly effective in decreasing
proteinuria, such as the administration of ACEIs or ARBs,
also decrease overall end organ injury. Whether these
beneficial effects are dependent on the reduction of
proteinuria has not been proven, in that these interventions
have multiple parallel effects that may all contribute to the
decrease of fibrosis [107].
Mechanisms of tubulointerstitial fibrosis
Tubulointerstitial fibrosis classically was thought merely to
reflect glomerular injury and resulting whole nephron
ischemia in most CKD. Interesting new data point to
independent mechanisms of interstitial fibrosis and the
importance of the tubulointerstitial lesion in progression.
Decreased peritubular capillary density, possibly modulated
by decreased VEGF or other angiogenic factors, has been
proposed as a mechanism in various progressive renal
diseases [108]. Future studies may demonstrate whether
these interstitial microvascular lesions are causal or conse-
quential in the development of interstitial injury.
Increased numbers of macrophages are closely correlat-
ed with both glomerulosclerosis and tubulointerstitial
fibrosis and are usually decreased by interventions that
decrease fibrosis. These cells are potential sources of
numerous cytokines and eicosanoids that affect the glo-
merulus [109]. Support for this hypothesis is seen with the
protective effects of maneuvers that decrease macrophage
influx. In a rat model of unilateral ureteral obstruction
(UUO), administration of ACEI ameliorated interstitial
monocyte/macrophage infiltration and decreased fibrosis
[110]. Studies in β6 integrin-deficient mice revealed that
infiltrating macrophages do not inevitably transduce fibrotic
effects; in these mice local activation of TGF-β is impaired,
and they are protected from fibrosis despite abundant
macrophage infiltration [61]. Macrophages may even play
a beneficial role in scarring. The specific role of the
macrophage AT1a receptor in renal fibrosis was examined
in studies of bone marrow transplantation in wild type mice
with UUO mice reconstituted with either wild type macro-
phages or macrophages devoid of the AT1a receptor. There
was more severe interstitial fibrosis in mice with the AT1a
deficient macrophages, even though fewer infiltrating
macrophages were observed, suggesting that the macro-
phage AT1a receptor functions to protect the kidney from
fibrogenesis [111].
In human diabetic nephropathy there is an early increase
in total interstitial cell volume (which may represent
increased cell size and/or number), preceding the accumu-
lation of interstitial collagen [112]. This is in contrast to the
diabetic glomerular lesion, where the expanded mesangial
area is largely due to increased matrix accumulation rather
than hypercellularity. These interstitial cells could possibly
represent interstitial myofibroblasts, postulated to play a
key role in interstitial fibrosis. These activated interstitial
cells are a major source of collagen synthesis, and increased
expression of α-smooth muscle actin (SMA), a marker of
myofibroblasts, predicts progressive renal dysfunction both
in human and experimental renal disease.
The source of interstitial myofibroblasts is a topic of
controversy. Bone marrow-derived or potential renal stem
cells may give rise not only to interstitial cells but also to
regenerating parenchymal cells [113]. Epithelial–mesen-
chymal transformation (EMT) is another possible mecha-
nism for generation of interstitial myofibroblasts [114]. This
seamless plasticity of cells changing from epithelial to
mesenchymal phenotypes exists during early development.
EMT may also occur in the adult after injury, contributing
approximately half of the interstitial fibroblasts in experi-
mental models [114]. Injured tubular epithelial cells can
change phenotype both in vivo and in vitro, with de novo
expression of a fibroblast-specific protein (FSP1), and
possibly migrate into the interstitium as myofibroblasts.
The surrounding matrix and basement membrane underly-
ing the tubular epithelium is disrupted by local proteolysis,
modulated by an array of cytokines and growth factors,
including insulin-like growth factors I and II, integrin-
linked kinases, EGF, FGF-2 and TGF-β [114]. Several key
factors inhibit EMT, including hepatocyte growth factor
and bone morphogenetic factor-7, and thus inhibit fibrosis
in experimental CKD [114].
Anatomic and genetic risks for CKD: nephron number
and gene polymorphisms
Risk for development of CKD and its rate of progression
varies in differing populations. CKD associated with
hypertension and arterio-nephrosclerosis is particularly
common in African Americans, and FSGS is more
frequently the underlying cause of steroid-resistant FSGS
in African Americans and Hispanics than in Caucasians
[115, 116]. These varying disease trends in differing ethnic
populations could represent both genetic and environmen-
tal factors. Low birth weight is epidemiologically linked to
increased risk for cardiovascular disease, hypertension and
CKD in adulthood. The link is postulated to be due to the
decreased nephron number that accompanies low term
birth weight, defined as less than 2,500 g [117, 118].
These fewer nephrons are postulated to be under greater
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sclerosis. Of interest, low birth weight is much more
common in African Americans than in Caucasians and is
not accounted for by socioeconomic status [119]. Further,
glomerular size in normal African Americans is larger than
in Caucasians and could possibly reflect smaller nephron
number [120]. In Australian Aborigines, marked increase
in incidence of CKD is associated with larger but fewer
glomeruli and low birth weight [121, 122]. Mechanisms
other than hemodynamic stress that could underlie these
differences in normal glomerular populations and also
relate to increased incidence of end-stage renal disease
include functional polymorphisms of genes that are
involved both in renal/glomerular development and con-
tribute to amplified scarring mechanisms, such as the
renin–angiotensin system [10].
African Americans also have increased severity of renal
disease associated with several systemic conditions. The
course of lupus nephritis in a prospective trial was more
severe in African Americans than in Caucasians, with more
extensive crescent formation and interstitial fibrosis and
greater likelihood of end-stage renal disease [123]. Even the
manifestations of HIV infection in the kidney differ
markedly between African Americans and Caucasians:
HIV-associated renal disease in African Americans is
typically an aggressive collapsing type of FSGS, contrasting
lower grade immune-complex-mediated glomerulonephriti-
des in Caucasians with HIV infection and renal disease
[124]. Genetic background also modulates susceptibility in
experimental models, both to podocyte injury (e.g. only the
balb/c mouse strain is susceptible to adriamycin) and to
hypertension injury (e.g. in the five-sixths nephrectomy
model, C57Bl mice are resistant, 129Sv/J mice are
susceptible) and even to diabetic injury [125–127].
There is also accumulating evidence that specific genes in
humans modulate the course and rate of organ damage.
Polymorphisms in several genes within the RAAS system,
including ACE, angiotensinogen and the angiotensin type 1
receptor, have been linked with cardiovascular and renal
disorders, including diabetic nephropathy, IgA nephropathy
and uropathies [128–133]. The ACE DD genotype, associated
with increased RAS activity, was increased in patients with IgA
nephropathy who ultimately experienced progressive decline in
renal function during follow-up compared with those whose
function remained stable over the same time [134].
Polymorphisms of TGF-β are also implicated in hyper-
tension and progressive fibrosis. The Arg 25 polymorphism
may be increased in African Americans, who may also have
greater elevation of circulating TGF-β when they reach
end-stage renal disease than do Caucasians [135].
These observations suggest that complex genetic traits
can modulate the response of glomerular cells to pathogenic
stimuli in experimental models. Whether ethnic differences
in development of renal disease in humans reflect contri-
butions of genetic and/or environmental influences remains
to be definitively determined.
QUESTIONS (Answers appear following the reference list)
1. A 6-year-old African American boy presented with
generalized edema, 24 h urine protein excretion of 1.5 g
and normal complements, and serum creatinine of
0.7 mg/dl. His blood pressure was 110/70 mmHg. His
nephrotic syndrome did not respond to an 8-week
course of steroids, and a renal biopsy is planned. The
most likely diagnosis in this patient is:
(a) FSGS due to mutation of podocin
(b) Minimal-change disease
(c) FSGS, usual type
(d) Diffuse mesangial sclerosis
(e) Collapsing glomerulopathy
2. For the same patient detailed in question 1, what
additional treatment should be initiated at this time to
decrease risk of CKD:
(a) Diuretics
(b) Spironolactone
(c) ACEIs
(d) Beta blockers
(e) ACEIs and ARBs
3. In the same patient detailed in the above questions,
what parameters would be most important to follow
and evaluate for adjustment of therapy:
(a) Edema
(b) White blood cell (WBC) count
(c) Blood pressure
(d) Proteinuria
4. A 14-year-old Caucasian girl was diagnosed with IgA
nephropathy, which on biopsy showed fibrocellular
crescents, with focal proliferative and secondary scle-
rosing lesions of glomeruli. Her urine protein excretion
was 1.0 g in 24 h. Urinalysis showed frequent red
blood cell casts, serum creatinine was 1.2 mg/dl and her
blood pressure was 120/93 mmHg. Which of the
following mechanisms are likely to contribute to
progression of her CKD:
(a) Podocyte loss
(b) Proteinuria
(c) Glomerular hypertension
(d) Infiltrating macrophages
(e) All of the above
5. A 10-year-old Caucasian boy with a history of multiple
episodes of steroid-dependent nephrotic syndrome
Pediatr Nephrol (2007) 22:2011–2022 2017since the age of 4 years now has proteinuria of 3.8 g in
24 h, with unremarkable urinalysis without red blood
cell casts; his serum creatinine is 0.6 mg/dl, and his
blood pressure is 98/64 mmHg. He has an increased
cholesterol level of 480 mg/dl and triglyceride levels
are 110 mg/dl. What mechanisms of renal injury are
likely to be activated in this child:
(a) podocyte loss
(b) proteinuria
(c) dyslipidemia
(d) glomerular hypertension
(e) (b) and (c)
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ANSWERS:
1. (c) is the correct answer. Podocin mutation occurs in only
up to approximately 25% of steroid-resistant NS patients.
Minimal-change disease is less likely, as he is steroid
resistant and African American. Diffuse mesangial
Pediatr Nephrol (2007) 22:2011–2022 2021sclerosis is very rare beyond early childhood. Although
collapsing glomerulopathy is more frequent in African
American than in Caucasian adults, this form of FSGS is
more rare than usual-type FSGS, especially in children.
2. (c) is the correct answer. ACEI is preferred as initial
treatment for proteinuric patients at risk for CKD, even
if they have normal blood pressure. If proteinuria does
not respond to ACEI alone, added treatment with ARB
may be considered, to decrease proteinuria and, likely,
to decrease the decline in GFR. Although diuretic
treatment may be warranted for edema, it does not have
specific effects to decrease risk of CKD. Spironolac-
tone may provide additional benefit based on early
results in proteinuric CKD patients, in addition to ACEI
and ARB. Beta blocker is not indicated in this patient
without hypertension.
3. (d) is the correct answer. In this normotensive patient, the
effect of therapy on proteinuria is the best indicator of
therapeutic efficacy. If the patient develops hypertension,
then normalization of blood pressure would be an
additional important target for therapy. Edema is also a
parameterforevaluationofneedfordiuretictreatmentbut
not of direct importance for progression of CKD. The
drugs listed do not have specific effects on WBC count.
4. (e) is the correct answer. In this patient with
sclerosing lesions, podocyte loss may contribute to
progressive damage. Proteinuria is also likely a
contributor to interstitial fibrosis, which may be
contributed to by infiltrating macrophages. Her blood
pressure is elevated, and she likely also has intra-
glomerular hypertension.
5. (e) is the correct answer. In this patient, the likely
underlying diagnosis is minimal-change disease, in that
hehassteroid-dependentnephroticsyndromeandstillhas
normalserumcreatinineafter6yearsofrelapsingdisease.
Podocyte loss is not a feature of minimal-change disease.
Proteinuria could be a contributor to interstitial fibrosis,
more likely if he does not just have selective proteinuria.
Dyslipidemia may contribute to renal as well as cardio-
vascular injury. His blood pressure is normal, as is his
serum creatinine, and therefore he likely has normal
intraglomerular pressure.
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